There was no consensus as to whether individuals with a GPV in an intermediate penetrance CSG (ATM, CHEK2, RAD51C, RAD51D, BARD1 or BRIP1) should be proactively recontacted regarding breast cancer surveillance at any stage, assuming that appropriate advice and onward referrals had been made after their results appointment. This evidence concerns the gene RAD51D and breast carcinoma.